Rize Oncology Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2018 - 2019
Net Income	-0.55	-0.69	-1.72	-1.64	-0.07	Upgrade
Stock-Based Compensation	0.03	0.18	0.62	0.88	0	Upgrade
Other Operating Activities	-0	-0.01	0	0	-	Upgrade
Change in Accounts Payable	0.04	-0.05	-0.13	0.21	0	Upgrade
Change in Other Net Operating Assets	0.02	0.1	0.04	-0.19	0	Upgrade
Operating Cash Flow	-0.47	-0.46	-1.18	-0.74	-0.07	Upgrade
Short-Term Debt Issued	-	-	-	-	0.1	Upgrade
Total Debt Issued	-	-	-	-	0.1	Upgrade
Net Debt Issued (Repaid)	-	-	-	-	0.1	Upgrade
Issuance of Common Stock	0.35	-	3	0.87	0	Upgrade
Financing Cash Flow	0.35	-	3	0.87	0.1	Upgrade
Foreign Exchange Rate Adjustments	-0.08	0.03	-0.2	-	-	Upgrade
Net Cash Flow	-0.2	-0.43	1.62	0.13	0.04	Upgrade
Levered Free Cash Flow	-0.28	-0.24	-0.54	-0.13	-0.04	Upgrade
Unlevered Free Cash Flow	-0.28	-0.24	-0.54	-0.13	-0.04	Upgrade
Change in Net Working Capital	-0.06	-0.05	0.08	-0.02	-0	Upgrade

Updated Nov 22, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.